Skip to content
Companies

Majesty Therapeutics

Early-stage biotechnology company founded in 2024 and based in the Lauderdale-by-the-Sea area of Florida

Raised to date

$100K

of $5M offered across 1 Form D filing

Still open
$4.9M
Investors
3
Last filed
May 15, 2026

About

It describes itself as transforming vascular and fibrotic disease through targeted biology, and its LinkedIn and PitchBook profiles frame the work as precision medicine for immune-mediated diseases. The company is operating in stealth: its website is a placeholder and no pipeline candidate or mechanism has been disclosed publicly. Its May 2026 Form D states that proceeds will fund research and development, trial design and regulatory filings, manufacturing, and working capital, and names Shawn Titcomb as chief executive and Ankit Bhargava as acting chief scientific officer.

Funding

  • Security to be acquiredFiled May 15, 2026Form D
    $100K/ $5M

Product

Targeted biology therapeutics program

Preclinical therapeutics

An undisclosed preclinical drug development program aimed at vascular and fibrotic disease using targeted biology, positioned by the company as precision medicine for immune-mediated conditions. No candidate name, target or mechanism has been made public while the company remains in stealth.

  • Preclinical stage, stealth mode
  • Focus on vascular and fibrotic disease
  • Precision-medicine approach to immune-mediated conditions

Built for

Patients with vascular and fibrotic disease, reached through clinicians and, at this stage, pharmaceutical partners and investors funding preclinical development.

People on file